The latest announcement is out from Vaccinex (VCNX).
Vaccinex, Inc. has announced new insights from its SIGNAL-AD Phase 1b/2 trial assessing the pepinemab antibody for treating Alzheimer’s disease. This update, which could potentially impact the company’s stock, is not intended for regulatory filing purposes but offers a glimpse into ongoing research and development efforts that could be significant for investors and stakeholders tracking advancements in Alzheimer’s treatments.
For detailed information about VCNX stock, go to TipRanks’ Stock Analysis page.
